These have recently been revised. Co-trimoxazole is now licensed for the treatment of urinary tract infections and acute exacerbations of chronic bronchitis but only where there is bacterial evidence of sensitivity to co-trimoxazole and good reason to prefer the combination to a single antibiotic. The circumstances where 'good reason' applies where not defined by the licensing authority.
In children, co-trimoxazole is licensed for the treatment of acute otitis media in children where there is good reason to prefer co-trimoxazole to a single antibiotic.
Co-trimoxazole is the first line treatment for pneumocystis carinii. The drug is also licensed for the treatment and prevention of toxoplasmosis and the treatment of nocardiasis.
Last reviewed 01/2018